These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38247866)

  • 21. The rise of covalent proteolysis targeting chimeras.
    Gabizon R; London N
    Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perilous journey: a tour of the ubiquitin-proteasome system.
    Kleiger G; Mayor T
    Trends Cell Biol; 2014 Jun; 24(6):352-9. PubMed ID: 24457024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Timer-based proteomic profiling of the ubiquitin-proteasome system reveals a substrate receptor of the GID ubiquitin ligase.
    Kong KE; Fischer B; Meurer M; Kats I; Li Z; Rühle F; Barry JD; Kirrmaier D; Chevyreva V; San Luis BJ; Costanzo M; Huber W; Andrews BJ; Boone C; Knop M; Khmelinskii A
    Mol Cell; 2021 Jun; 81(11):2460-2476.e11. PubMed ID: 33974913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System.
    Radhakrishnan S; Hoff O; Muellner MK
    Molecules; 2022 Nov; 27(23):. PubMed ID: 36500212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
    Nalawansha DA; Crews CM
    Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox.
    Siepe DH; Picton LK; Garcia KC
    ACS Synth Biol; 2023 Apr; 12(4):1081-1093. PubMed ID: 37011906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recognition of substrate degrons by E3 ubiquitin ligases and modulation by small-molecule mimicry strategies.
    Lucas X; Ciulli A
    Curr Opin Struct Biol; 2017 Jun; 44():101-110. PubMed ID: 28130986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical discussion on the relationship between E3 ubiquitin ligases, protein degradation, and skeletal muscle wasting: it's not that simple.
    Hughes DC; Goodman CA; Baehr LM; Gregorevic P; Bodine SC
    Am J Physiol Cell Physiol; 2023 Dec; 325(6):C1567-C1582. PubMed ID: 37955121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The E3 ubiquitin ligase thyroid hormone receptor-interacting protein 12 targets pancreas transcription factor 1a for proteasomal degradation.
    Hanoun N; Fritsch S; Gayet O; Gigoux V; Cordelier P; Dusetti N; Torrisani J; Dufresne M
    J Biol Chem; 2014 Dec; 289(51):35593-604. PubMed ID: 25355311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
    VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
    J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activity-dependent self-degradation.
    Xie Y; Avello M; Schirle M; McWhinnie E; Feng Y; Bric-Furlong E; Wilson C; Nathans R; Zhang J; Kirschner MW; Huang SM; Cong F
    J Biol Chem; 2013 Feb; 288(5):2976-85. PubMed ID: 23184937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How the ends signal the end: Regulation by E3 ubiquitin ligases recognizing protein termini.
    Sherpa D; Chrustowicz J; Schulman BA
    Mol Cell; 2022 Apr; 82(8):1424-1438. PubMed ID: 35247307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanding PROTACtable genome universe of E3 ligases.
    Liu Y; Yang J; Wang T; Luo M; Chen Y; Chen C; Ronai Z; Zhou Y; Ruppin E; Han L
    Nat Commun; 2023 Oct; 14(1):6509. PubMed ID: 37845222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
    He M; Cao C; Ni Z; Liu Y; Song P; Hao S; He Y; Sun X; Rao Y
    Signal Transduct Target Ther; 2022 Jun; 7(1):181. PubMed ID: 35680848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.
    Kannt A; Đikić I
    Cell Chem Biol; 2021 Jul; 28(7):1014-1031. PubMed ID: 33945791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-degron-mediated degradation and regulation of mitochondrial PINK1 kinase.
    Eldeeb MA; Ragheb MA
    Curr Genet; 2020 Aug; 66(4):693-701. PubMed ID: 32157382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rotavirus NSP1 Associates with Components of the Cullin RING Ligase Family of E3 Ubiquitin Ligases.
    Lutz LM; Pace CR; Arnold MM
    J Virol; 2016 Jul; 90(13):6036-48. PubMed ID: 27099313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
    Singh H; Agrawal DK
    Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.